Lyell Immunopharma, Inc. (LYEL)
NASDAQ: LYEL · Real-Time Price · USD
0.613
-0.028 (-4.42%)
Dec 20, 2024, 4:00 PM EST - Market closed
Lyell Immunopharma Ratios and Metrics
Market cap in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Current | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
| Dec '24 Dec 20, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
| Market Capitalization | 171 | 489 | 865 | 1,861 | - | - |
| Market Cap Growth | -4.26% | -43.52% | -53.52% | - | - | - |
| Enterprise Value | -231 | -45 | 182 | 992 | - | - |
| Last Close Price | 0.61 | 1.94 | 3.47 | 7.74 | - | - |
| PS Ratio | 5607.69 | 3758.66 | 10.22 | 174.77 | - | - |
| PB Ratio | 0.30 | 0.75 | 1.04 | 2.00 | - | - |
| P/TBV Ratio | 0.67 | 0.75 | 1.04 | 2.00 | - | - |
| EV/Sales Ratio | - | - | 2.15 | 93.15 | - | - |
| Debt / Equity Ratio | 0.11 | 0.10 | 0.08 | 0.07 | 0.08 | 0.07 |
| Debt / FCF Ratio | - | - | - | - | - | 1.17 |
| Asset Turnover | 0.00 | 0.00 | 0.08 | 0.01 | 0.01 | - |
| Quick Ratio | 13.15 | 15.82 | 17.29 | 13.15 | 12.43 | 19.78 |
| Current Ratio | 13.43 | 16.07 | 17.59 | 13.40 | 12.53 | 19.97 |
| Return on Equity (ROE) | -33.22% | -31.53% | -20.77% | -30.36% | -36.30% | - |
| Return on Assets (ROA) | -19.12% | -18.18% | -11.32% | -13.11% | -18.76% | - |
| Return on Capital (ROIC) | -20.00% | -18.95% | -12.31% | -15.08% | -22.73% | - |
| Earnings Yield | -119.24% | -48.02% | -21.17% | -13.44% | - | - |
| FCF Yield | -91.32% | -34.05% | -22.40% | -10.30% | - | - |
| Buyback Yield / Dilution | -1.82% | -1.58% | -81.79% | -925.18% | -144.21% | - |
| Total Shareholder Return | -1.82% | -1.58% | -81.79% | -925.18% | -144.21% | - |
Source: S&P Capital IQ. Standard template.
Financial Sources.